ArticleArthritis research & therapy2026
Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States.
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis United States (US)-based claims analysis evaluated the real-world safety of tofacitinib versus biologic treatments in patients with psoriatic arthritis (PsA). Risk of serious infections, myocardial infarction (MI) or stroke, venous thromboembolism (VTE), and malignancy (excluding non-melanoma skin cancer) were assessed using data from a US real-world database of administrative data and claims from medical/pharmacy insurances (Komodo Health).
methodsPatients with PsA aged ≥ 18 years who initiated tofacitinib or a biologic treatment (tumor necrosis factor inhibitors [TNFi], interleukin-17 A inhibitors [IL-17Ai], risankizumab or ustekinumab) between December 2017–February 2023, with ≥ 12 months of prior continuous enrollment, were included. Crude incidence rates (IRs)/100 patient-years (PY) and stabilized inverse probability treatment weighting (sIPTW) were calculated. Cox proportional hazards models with sIPTW were used to calculate adjusted hazard ratios with bootstrapping for 95% confidence intervals.
resultsIn total, 48,167 patients were included (tofacitinib, N = 3,166; TNFi, N = 26,760; IL-17Ai, N = 20,252; risankizumab, N = 4,381; ustekinumab, N = 4,499). Mean age at index ranged from 48.2 to 50.3 years; mean follow-up was 288.5–347.0 days. Crude IRs/100 PY ranged from 1.78 to 2.53 for serious infections, 0.27–0.61 for MI/stroke, 0.17–0.42 for VTE, and 0.74–1.06 for malignancy. In the main analysis, there were no statistically significant differences in the risk of developing serious infections, MI or stroke, or malignancy between treatments. Patients initiating tofacitinib versus TNFi (but not other biologics) had significantly higher VTE risk. A higher proportion of tofacitinib initiators had surgery (potential VTE risk factor) during the baseline period (45.9–46.7%) and 6 months post-index (28.1–28.9%), versus biologic initiators (40.2–44.3% and 22.2–27.4%, respectively).
conclusionsIn patients with PsA who were not enriched for cardiovascular/VTE risk factors, no significant differences in the risk of serious infections, MI or stroke, or malignancy were reported in patients initiating tofacitinib versus biologic treatments. Tofacitinib was associated with a higher risk of VTE compared with TNFi, aligning with previous clinical data. Limitations included the low number of safety events, residual confounding, and factors associated with claims data. EUROPEAN UNION POST-AUTHORISATION STUDY (PAS) REGISTER NUMBER: EUPAS103443.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.